Oral and intramuscular administration of vitamin D in patients with nonalcoholic fatty liver
Phase 2
Recruiting
- Conditions
- on-alcoholic fatty liver.Fatty (change of) liver, not elsewhere classifiedK76.0
- Registration Number
- IRCT20190701044062N2
- Lead Sponsor
- Vice chancellor for research, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Adult Patients Over 18 Years With Non-alcoholic Fatty Liver Disease (NAFLD) Based on Diagnosis of Gastroenterologist Osteatogenic drugs
vitamin D deficiency (25-hydroxyvitamin D level less than 20 ng / ml), and informed patient consent to participate in the study
informed patient consent to participate in the study
Exclusion Criteria
Alcohol consumption
hereditary history
osteogenic drugs
hepatitis
metabolic diseases
Recent consumption of vitamin D
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vitamin D levels in both groups will be measured at baseline. One group of patients will be treated with oral vitamin D (pear vitamin D) at 50,000 units weekly for one month and then 50,000 units monthly for one month. In the second group, patients will receive vitamin D of 300,000 units two months apart. The level of 25-hydroxyvitamin D in both groups will be re-measured 2 months after the start of treatment. The primary outcome of the present study was the level of 25-hydroxyvitamin D levels 3 months after initiation of vitamin D treatment. Timepoint: Vitamin D levels in both groups will be measured at baseline. It will be re-measured 2 months after the start of treatment. Method of measurement: blood test.
- Secondary Outcome Measures
Name Time Method